- Going concern
- Material uncertainty
- Principal risks
- 12
| 8 Oct 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Jan 2025 | Annual Report and Accounts 2023-2024 | |
| 29 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
| 14 Oct 2024 | Preclinical RXC008 data at UEG | |
| 20 Aug 2024 | Expert panel at IPF summit | |
Redx Pharma is a biotech company in the clinical stage that specializes in finding and creating new, precise, small molecule treatments for cancer and fibrosis.
| 8 Oct 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Jan 2025 | Annual Report and Accounts 2023-2024 | |
| 29 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
| 14 Oct 2024 | Preclinical RXC008 data at UEG | |
| 20 Aug 2024 | Expert panel at IPF summit | |
Redx Pharma is a biotech company in the clinical stage that specializes in finding and creating new, precise, small molecule treatments for cancer and fibrosis.
| 28 Jun 2024 |
| Encouraging zamaporvint Phase II data at ESMO GI |
| 20 Jun 2024 | Zamaporvint Phase II data presentation at ESMO GI |
| 14 Jun 2024 | RXC008 preclinical data in oral presentation at ECM Congress |
| 14 May 2024 | Changes to board composition |
| 1 May 2024 | AIM cancellation |
| 1 May 2024 | REDX shares now trading on JP Jenkins |
| 28 Jun 2024 |
| Encouraging zamaporvint Phase II data at ESMO GI |
| 20 Jun 2024 | Zamaporvint Phase II data presentation at ESMO GI |
| 14 Jun 2024 | RXC008 preclinical data in oral presentation at ECM Congress |
| 14 May 2024 | Changes to board composition |
| 1 May 2024 | AIM cancellation |
| 1 May 2024 | REDX shares now trading on JP Jenkins |